Molecular Test Identifies Acute Transplant Rejection
By LabMedica International staff writers Posted on 25 Nov 2014 |
The development of noninvasive molecular assays to improve disease diagnosis and patient monitoring is a critical need in renal transplantation, as acute rejection (AR) increases the risk for chronic graft injury and failure.
Acute rejection after kidney transplantation occurs in about 15% to 20% of patients despite immunosuppressive therapy and rejection is usually heralded by an increase in the patient's serum creatinine which is a marker of kidney function, and a kidney biopsy is then performed to confirm whether rejection is taking place.
Scientists at the University of California (San Francisco, CA, USA) working with an international team used 558 peripheral blood (PB) samples from 438 adult and pediatric renal transplant patients from eight renal transplant centers in the United States, Mexico, and Spain and enrolled between 2005 and 2012 to develop a quantitative real-time polymerase chain reaction (qPCR) test. They developed the test in 143 samples from adults with and without acute rejection as determined by kidney biopsy, and then finalized and validated the test in three cohorts of patients.
Total ribonucleic acid (RNA) was extracted using the column-based method kits and was measured for RNA integrity using the RNA 6000 Nano LabChip Kit on a 2100 Bioanalyzer (Agilent Technologies; Santa Clara, CA, USA). Microfluidic qPCR was performed on the 96.96 dynamic array and the chip loaded via the HX IFC Controller and performing the qPCR in the BioMark qPCR platform (Fluidigm; South San Francisco, CA, USA).
The team evaluated the differential expression of 10 out of 43 genes, selecting the same ten genes that have been validated as diagnostic for AR in PB using standardized clinical trial sample collection and processing protocols. To improve the diagnostic accuracy for AR in the 143 adult samples, various statistical modeling methods were used to include an additional seven genes which improved the accuracy of the gene panel for discriminating AR from No-AR samples, for a final selection of 17 genes. The assay was called kSORT and was able to classify patients as high risk versus low risk for AR. The kSORT assay was able to detect AR in blood independent of age, time post-transplantation, and sample source without additional data normalization.
The authors concluded that the kSORT assay is a simple, robust, and clinically applicable blood test. They are using kSORT in a prospective observational trial as well as a second prospective, randomized, double-blinded clinical interventional trial, which will establish how kSORT can be used serially post-transplant to complement current clinical practice guidelines for stratifying patient immune risk, medication load, and requirement for biopsy. The study was published on November 11, 2014, in the journal Public Library of Science Medicine.
Related Links:
University of California
Agilent Technologies
Fluidigm
Acute rejection after kidney transplantation occurs in about 15% to 20% of patients despite immunosuppressive therapy and rejection is usually heralded by an increase in the patient's serum creatinine which is a marker of kidney function, and a kidney biopsy is then performed to confirm whether rejection is taking place.
Scientists at the University of California (San Francisco, CA, USA) working with an international team used 558 peripheral blood (PB) samples from 438 adult and pediatric renal transplant patients from eight renal transplant centers in the United States, Mexico, and Spain and enrolled between 2005 and 2012 to develop a quantitative real-time polymerase chain reaction (qPCR) test. They developed the test in 143 samples from adults with and without acute rejection as determined by kidney biopsy, and then finalized and validated the test in three cohorts of patients.
Total ribonucleic acid (RNA) was extracted using the column-based method kits and was measured for RNA integrity using the RNA 6000 Nano LabChip Kit on a 2100 Bioanalyzer (Agilent Technologies; Santa Clara, CA, USA). Microfluidic qPCR was performed on the 96.96 dynamic array and the chip loaded via the HX IFC Controller and performing the qPCR in the BioMark qPCR platform (Fluidigm; South San Francisco, CA, USA).
The team evaluated the differential expression of 10 out of 43 genes, selecting the same ten genes that have been validated as diagnostic for AR in PB using standardized clinical trial sample collection and processing protocols. To improve the diagnostic accuracy for AR in the 143 adult samples, various statistical modeling methods were used to include an additional seven genes which improved the accuracy of the gene panel for discriminating AR from No-AR samples, for a final selection of 17 genes. The assay was called kSORT and was able to classify patients as high risk versus low risk for AR. The kSORT assay was able to detect AR in blood independent of age, time post-transplantation, and sample source without additional data normalization.
The authors concluded that the kSORT assay is a simple, robust, and clinically applicable blood test. They are using kSORT in a prospective observational trial as well as a second prospective, randomized, double-blinded clinical interventional trial, which will establish how kSORT can be used serially post-transplant to complement current clinical practice guidelines for stratifying patient immune risk, medication load, and requirement for biopsy. The study was published on November 11, 2014, in the journal Public Library of Science Medicine.
Related Links:
University of California
Agilent Technologies
Fluidigm
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Molecular Diagnostics News
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset